acarbose

Overview

Acarbose is an orally administered antidiabetic drug used primarily to reduce postprandial hyperglycemia. It acts as an inhibitor of intestinal carbohydrate-digesting enzymes, especially α-glucosidase, and is also commonly used as a reference inhibitor in studies of α-amylase and related carbohydrate-hydrolyzing targets. By slowing the breakdown of complex carbohydrates into absorbable monosaccharides, acarbose reduces the rate at which glucose enters the bloodstream after meals.

In biomedical research, acarbose is frequently used as a benchmark compound for evaluating new α-glucosidase inhibitors, antidiabetic natural products, and synthetic small molecules. In the recent studies summarized here, it served both as a comparator drug and as a target-related reference in assays examining enzyme inhibition, docking, and postprandial glucose control. The surrounding research context also links acarbose to broader metabolic and functional-food investigations involving alpha-glucosidase, amylase alpha 1C, obesity, and hyperinsulinemic T2D patients.

Focus of Latest Publications

Recent publications have continued to use acarbose as a reference standard for evaluating new antidiabetic approaches, most often in studies centered on intestinal carbohydrate-digesting enzymes and postprandial glycemic control. Several reports compared experimental compounds or extracts against acarbose in alpha-glucosidase or alpha-amylase inhibition assays, reflecting its role as a benchmark therapy for reducing postprandial glucose excursions. In these studies, acarbose was used alongside in vitro enzyme assays, molecular docking, and in some cases in vivo glucose-loading models to contextualize the potency of newly identified candidates.

Multiple natural-product studies reported activity approaching or exceeding that of acarbose. Chia seed methanolic extract produced a glycemic curve comparable to acarbose in normoglycemic Wistar rats after oral sucrose challenge, while rosmarinic acid and its hexoside showed docking affinities toward alpha-glucosidase targets close to those of acarbose. In Garcinia nujiangensis, one biphenyl derivative was described as approximately 7 times stronger than acarbose as an alpha-glucosidase inhibitor. Similarly, Fagonia cretica extract showed alpha-amylase inhibition that was weaker than acarbose, but docking highlighted quercetin, luteolin, and catechin as strong binders to antidiabetic targets. Pomegranate-husk-derived ZnO nanoparticles also inhibited alpha-amylase and pancreatic lipase at levels comparable to standard drugs such as acarbose and orlistat.

Synthetic and peptide-based studies likewise used acarbose as the comparator for improved enzyme inhibition. A modified food-derived peptide, YAPSW, inhibited alpha-glucosidase more strongly than both its parent peptide and acarbose, and also improved insulin resistance-related signaling. Thiazole-hydrazine-isoindole hybrids, especially TR6, showed markedly greater alpha-glucosidase inhibition than acarbose and favorable in silico drug-likeness. Methyl-glycosyl furanose-based sulfonium inhibitors displayed potent maltase, sucrase, and isomaltase inhibition, with several compounds matching or surpassing acarbose; notably, acarbose was reported to be almost inactive against isomaltase in that study. In vivo, LY-23 reduced postprandial blood glucose in mice after maltose or sucrose loading with efficacy comparable to voglibose and acarbose.

Other publications reinforced acarbose’s role as a comparator in broader antidiabetic screening. N-propylcarbazole-1,3-thiazole hybrid 5k outperformed acarbose in alpha-glucosidase inhibition and reduced postprandial glucose in zebrafish with comparable efficacy to acarbose. Pyrrole-based imidazothiazole derivatives also showed stronger alpha-amylase and alpha-glucosidase inhibition than acarbose, with compound 8 emerging as a leading candidate. Across these studies, acarbose served as the principal reference for gauging enzyme-inhibitory potency, helping position new natural, synthetic, and nanomaterial-based candidates for further development in glycemic management.

Key Publications

NEWJun Unlocking the Role of Chia (Salvia hispanica L.) Seed Phenolic Metabolites in Postprandial Glucose Modulation: in vitro, in vivo, and Antioxidant Evidence Supported by Molecular Docking. (Plant foods for human nutrition (Dordrecht, Netherlands), 2026, PMID 42313210): "Docking analyses revealed that rosmarinic acid and its hexoside displayed high binding affinities (-7.7 to -8.1 kcal/mol) toward α-glucosidase targets, closely approaching those of acarbose (-7.9 to -9.1 kcal/mol) and exceeding those of caffeic-acid derivatives, supporting their potential contribution to the in vitro and in vivo responses."
NEWJun Bioactive biphenyl derivatives from Garcinia nujiangensis and structural revision. (Fitoterapia, 2026, PMID 42297079): "Notably, compound 10 (IC50 = 37.80 ± 1.43 μg·mL-1) was identified as the most potent α-glucosidase inhibitor, which was approximately 7 times stronger than the positive control (acarbose)."
Jun Liquid Chromatography-Electrospray Ionization-Tandem Mass Spectrometry Profiling, Antioxidant, Antibacterial, and Antidiabetic Properties of Fagonia cretica L.: Insights From In Vitro and In Silico Approaches. (ChemistryOpen, 2026, PMID 42168772): "Inhibition of α-amylase was observed, indicating weak to modest metabolic benefits, though less potent than acarbose."
May Green synthesis of ZnO nanoparticles using pomegranate husk extract: comparative evaluation of antioxidant, enzyme inhibition, and cytotoxic properties. (Artificial cells, nanomedicine, and biotechnology, 2026, PMID 42142531): "Both types of ZnO NPs demonstrated notable antioxidant activity (>62% scavenging in DPPH and ABTS assays) and strong inhibitory effects against pancreatic lipase and α-amylase (>70%), comparable to standard drugs such as orlistat and acarbose."
May Rational Sequence Modification Upgrades a Food-Derived Peptide into a Stronger Dual-Functional Regulator of α-Glucosidase Activity and Insulin Resistance. (Journal of agricultural and food chemistry, 2026, PMID 42118964): "However, its activity was weaker than acarbose."
Apr Structure-based design and molecular modelling of n-propylcarbazole-1,3-thiazole hybrids as potent α-glucosidase inhibitors: Kinetic, in vitro, and in vivo evaluation. (Journal of molecular graphics & modelling, 2026, PMID 42033845): "Among them, compound (5k) exhibited outstanding inhibitory potency (IC50 = 6.25 ± 0.17 μM), significantly surpassing the reference drug acarbose (IC50 = 118.09 ± 8.39 μM)."
Apr Evaluation of the underutilized Malpighia glabra L. fruits as a future functional food: nutritional composition, phenolic profile, biological activities, and synergistic effects with pharmaceutical drugs. (Food & function, 2026, PMID 41944642): "Synergistic interactions were observed in vitro between the extract and acarbose (an anti-diabetic drug)."
Jun Design, synthesis, in vitro and in silico evaluation of thiazole-hydrazine hybrids incorporating an isoindole-1,3-dione scaffold as potent α-glucosidase inhibitors. (Bioorganic chemistry, 2026, PMID 41855632): "Notably, the most active compound, TR6 (KI: 0.452 ± 0.093 μM), demonstrated approximately 15-fold greater potency compared to the reference drug acarbose (KI: 6.748 ± 0.167 μM), highlighting the substantial enhancement achieved through the designed scaffold modification."
May Design, synthesis of novel methyl-glycosyl furanose based sulfonium type α-glucosidase inhibitors with potent antihyperglycemic activity. (European journal of medicinal chemistry, 2026, PMID 41849948): "Remarkably, in vivo studies revealed that the oral administration of LY-23 (1.0 or 10.0 mg/kg) effectively reduced postprandial blood glucose levels in normal ICR mice following maltose or sucrose loading, with an efficacy comparable to that of voglibose (1.0 mg/kg) and acarbose (20.0 mg/kg), respectively."
Jun Tailored pyrrole-based imidazothiazole scaffolds: Synthetic elaboration, enzyme kinetic profiling and DFT-guided molecular docking toward Antidiabetic therapeutics. (Computational biology and chemistry, 2026, PMID 41576694): "which outperformed the potential of acarbose (6.20 ± 0.10 and 6.70 ± 0.20 µM), a reference drug."